The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 5: 716 - 723

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.05.015

Clinical Research

The predictive value of the systemic inflammation response index for non⁃curative resection after endoscopic submucosal dissection for early colorectal cancer

  • Jiyue ZHU ,
  • Bo ZHANG ,
  • Yaru LI ,
  • Liuye. HUANG
Expand
  • *.Department of Clinical Medicine，Qingdao University，Qingdao 266071，Shandong，China

Received date: 2024-11-25

  Online published: 2025-03-20

Fold

Abstract

Objective To evaluate the predictive value of the Systemic Inflammation Response Index （SIRI） for non?curative resection during endoscopic submucosal dissection （ESD） treatment of early?stage colorectal cancer （CRC）， and to develop a nomogram?based prediction model. Methods Retrospective data were collected from 235 patients diagnosed with early?stage CRC who underwent ESD at our hospital between January 2016 and August 2024. Receiver operating characteristic （ROC） curves were constructed to evaluate the predictive performance of inflammatory markers， such as the SIRI， for non?curative resection following ESD. Logistic regression analysis was conducted to identify independent risk factors associated with non?curative resection， and a prediction model was developed based on these factors. The model was internally validated. Results The incidence of non?curative resection in the study population was 26.38% （62 out of 235 cases）. Inflammatory markers， specifically SIRI and SII， demonstrated predictive value for non?curative resection following ESD in patients with early?stage CRC， with SIRI exhibiting a higher predictive accuracy （AUC = 0.704）. Logistic regression analysis identified age， family history， CEA， SIRI， and SII as independent risk factors for non?curative resection （all P < 0.05）. Based on these findings， a nomogram prediction model incorporating age， family history， CEA， and SIRI was developed， achieving a C?index of 0.741 （95% CI： 0.675 ~ 0.806）. The model's performance was validated using the Bootstrap method， and the decision curve analysis indicated satisfactory predictive accuracy. Conclusions SIRI demonstrates superior predictive value compared to SII for non?curative resection following ESD in patients with early?stage CRC. Independent risk factors for non?curative resection after ESD include age， family history， CEA levels， SIRI， and SII. A nomogram prediction model constructed using these risk factors?specifically age， family history， CEA levels， and SIRI?can effectively predict the likelihood of non?curative resection after ESD.

Key words： systemic inflammation response index; early colorectal cancer; endoscopic submucosal dissection; non-curative resection

Cite this article

Jiyue ZHU , Bo ZHANG , Yaru LI , Liuye. HUANG . The predictive value of the systemic inflammation response index for non⁃curative resection after endoscopic submucosal dissection for early colorectal cancer[J]. The Journal of Practical Medicine, 2025 , 41(5) : 716 -723 . DOI: 10.3969/j.issn.1006-5725.2025.05.015

References

1 BRAY F， LAVERSANNE M， SUNG H， et al. Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin， 2024， 74（3）： 229-263. doi:10.3322/caac.21834
2 XI Y， XU P. Global colorectal cancer burden in 2020 and projections to 2040 ［J］. Transl Oncol， 2021， 14（10）： 101174. doi:10.1016/j.tranon.2021.101174
3 HASHIGUCHI Y， MURO K， SAITO Y， et al. Japanese Society for Cancer of the Colon and Rectum （JSCCR） guidelines 2019 for the treatment of colorectal cancer ［J］. Int J Clin Oncol， 2020， 25（1）： 1-42. doi:10.1007/s10147-019-01485-z
4 MAIORINO L， LER-PLENKER J DA， SUN L， et al. Innate Immunity and Cancer Pathophysiology ［J］. Annu Rev Pathol， 2022， 17： 425-457. doi:10.1146/annurev-pathmechdis-032221-115501
5 KHANDIA R， MUNJAL A. Interplay between inflammation and cancer ［J］. Adv Protein Chem Struct Biol， 2020， 119： 199-245. doi:10.1016/bs.apcsb.2019.09.004
6 KASPRZAK A. The Role of Tumor Microenvironment Cells in Colorectal Cancer （CRC） Cachexia ［J］. Int J Mol Sci， 2021， 22（4）： 1565. doi:10.3390/ijms22041565
7 SCHMITT M， GRETEN F R. The inflammatory pathogenesis of colorectal cancer ［J］. Nat Rev Immunol， 2021， 21（10）：653-667. doi:10.1038/s41577-021-00534-x
8 NADEEM M S， KUMAR V， AL-ABBASI F A， et al. Risk of colorectal cancer in inflammatory bowel diseases ［J］. Semin Cancer Biol， 2020， 64： 51-60. doi:10.1016/j.semcancer.2019.05.001
9 LIEW P X， KUBES P. The Neutrophil's Role During Health and Disease ［J］. Physiol Rev， 2019， 99（2）： 1223-1248. doi:10.1152/physrev.00012.2018
10 KHAN U， CHOWDHURY S， BILLAH M M， et al. Neutrophil Extracellular Traps in Colorectal Cancer Progression and Metastasis ［J］. Int J Mol Sci， 2021， 22（14）： 7260. doi:10.3390/ijms22147260
11 ARPINATI L， SHAUL M E， KAISAR-ILUZ N， et al. NETosis in cancer： a critical analysis of the impact of cancer on neutrophil extracellular trap （NET） release in lung cancer patients vs. mice ［J］. Cancer Immunol Immunother， 2020， 69（2）： 199-213. doi:10.1007/s00262-019-02474-x
12 DI MITRI D， TOSO A， CHEN J J， et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer ［J］. Nature， 2014， 515（7525）： 134-137. doi:10.1038/nature13638
13 GUGLIETTA S， KRIEG C. Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies ［J］. Blood Rev， 2023， 58： 101012. doi:10.1016/j.blre.2022.101012
14 BAMBACE N M， HOLMES C E. The platelet contribution to cancer progression ［J］. J Thromb Haemost， 2011， 9（2）： 237-249. doi:10.1111/j.1538-7836.2010.04131.x
15 HAEMMERLE M， STONE R L， MENTER D G， et al. The Platelet Lifeline to Cancer： Challenges and Opportunities ［J］. Cancer Cell， 2018， 33（6）： 965-983. doi:10.1016/j.ccell.2018.03.002
16 FARAG C M， ANTAR R， AKOSMAN S， et al. What is hemoglobin， albumin， lymphocyte， platelet （HALP） score？ A comprehensive literature review of HALP's prognostic ability in different cancer types ［J］. Oncotarget， 2023， 14： 153-172. doi:10.18632/oncotarget.28367
17 TIAN B W， YANG Y F， YANG C C， et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy： Systemic review and meta-analysis ［J］. Immunotherapy， 2022， 14（18）： 1481-1496. doi:10.2217/imt-2022-0133
18 MENYHART O， FEKETE J T， GY?RFFY B. Inflammation and Colorectal Cancer： A Meta-Analysis of the Prognostic Significance of the Systemic Immune-Inflammation Index （SII） and the Systemic Inflammation Response Index （SIRI） ［J］. Int J Mol Sci， 2024， 25（15）： 8841. doi:10.3390/ijms25158441
19 YAMAMOTO T， KAWADA K， Obama K. Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients ［J］. Int J Mol Sci， 2021， 22（15）： 8002. doi:10.3390/ijms22158002
20 LAKEMEYER L， SANDER S， WITTAU M， et al. Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer ［J］. Diseases， 2021， 9（1）： 21. doi:10.3390/diseases9010021
21 KASTRINOS F， SAMADDER N J， BURT R W. Use of Family History and Genetic Testing to Determine Risk of Colorectal Cancer ［J］. Gastroenterology， 2020， 158（2）： 389-403. doi:10.1053/j.gastro.2019.11.029
22 LAI C C， YOU J F， YEH C Y， et al. Low preoperative serum albumin in colon cancer： A risk factor for poor outcome ［J］. Int J Colorectal Dis， 2011， 26（4）： 473-481. doi:10.1007/s00384-010-1113-4
23 KEUM N， GIOVANNUCCI E. Global burden of colorectal cancer： emerging trends， risk factors and prevention strategies ［J］. Nat Rev Gastroenterol Hepatol， 2019， 16（12）： 713-732. doi:10.1038/s41575-019-0189-8
24 BOTTERI E， BORRONI E， SLOAN E K， et al. Smoking and colorectal cancer risk， overall and by molecular subtypes： A meta-analysis ［J］. Am J Gastroenterol， 2020， 115（12）： 1940-1949. doi:10.14309/ajg.0000000000000803
Options
Outlines

/

〈 〉